Heart rhythm · 2026
Interatrial block in hypertrophic cardiomyopathy: Associations with left atrial remodeling and adverse atrial outcomes.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anmad-Shihadeh Leydimar Adel, Teis Albert, Sabate Marta, Casas Guillem, De Raffele Martina, Weerts Jeremy, Limeres Javier, Guillen Marzo Marta, Rodríguez Palomares Jose F, Delgado Victoria, Cediel German
Аннотация
BACKGROUND: Interatrial block (IAB) has been associated with atrial fibrillation (AF) and stroke in broader cardiovascular populations. Whether these associations extend to hypertrophic cardiomyopathy (HCM) and how IAB relates to underlying left atrial (LA) remodeling remain unknown.
OBJECTIVE: This study aimed to investigate the prevalence, morphofunctional correlates, and prognostic value of IAB in patients with HCM.
METHODS: This multicenter study included 259 patients with HCM without a history of AF/stroke. IAB was defined by a P-wave duration of >120 ms. Associations between morphologic and functional parameters of the LA and IAB were assessed using cardiac magnetic resonance imaging. The primary composite endpoint was new-onset AF, transient ischemic attack, or ischemic stroke.
RESULTS: IAB was present in 10% of the cohort. Patients with IAB exhibited larger LA diameter (median 47.4 vs 43.2 mm; P = .022), larger indexed maximum LA volume (median 52.5 vs 46.9 mL/m2; P = .043), impaired LA ejection fraction (median 48% vs 51%; P = .043), reduced LA reservoir strain (median 22.0% vs 29.3%; P = .018), and reduced LA conduit strain (median 8.3% vs 12.1%; P = .012). During a median 5.8-year follow-up, IAB was independently associated with a 2-fold increased risk of the composite endpoint (hazard ratio 2.11; 95% confidence interval 1.13-3.95; P = .019) and new-onset AF (hazard ratio 2.10; 95% confidence interval 1.07-4.16; P = .031).
CONCLUSION: In patients with HCM, IAB is associated with significant LA structural and functional impairments, indicative of advanced atrial cardiomyopathy. Its presence was independently associated with an increased risk of incident AF and stroke, suggesting its value as a simple, accessible electrocardiographic marker for enhanced risk stratification.
OBJECTIVE: This study aimed to investigate the prevalence, morphofunctional correlates, and prognostic value of IAB in patients with HCM.
METHODS: This multicenter study included 259 patients with HCM without a history of AF/stroke. IAB was defined by a P-wave duration of >120 ms. Associations between morphologic and functional parameters of the LA and IAB were assessed using cardiac magnetic resonance imaging. The primary composite endpoint was new-onset AF, transient ischemic attack, or ischemic stroke.
RESULTS: IAB was present in 10% of the cohort. Patients with IAB exhibited larger LA diameter (median 47.4 vs 43.2 mm; P = .022), larger indexed maximum LA volume (median 52.5 vs 46.9 mL/m2; P = .043), impaired LA ejection fraction (median 48% vs 51%; P = .043), reduced LA reservoir strain (median 22.0% vs 29.3%; P = .018), and reduced LA conduit strain (median 8.3% vs 12.1%; P = .012). During a median 5.8-year follow-up, IAB was independently associated with a 2-fold increased risk of the composite endpoint (hazard ratio 2.11; 95% confidence interval 1.13-3.95; P = .019) and new-onset AF (hazard ratio 2.10; 95% confidence interval 1.07-4.16; P = .031).
CONCLUSION: In patients with HCM, IAB is associated with significant LA structural and functional impairments, indicative of advanced atrial cardiomyopathy. Its presence was independently associated with an increased risk of incident AF and stroke, suggesting its value as a simple, accessible electrocardiographic marker for enhanced risk stratification.